NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 16th January 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Dr Ian Bernstein Present for all items
4. Dr Craig Buckley Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Patrick De Barr Items 1.1 to 4.2.2

and 6.1 to 6.3.2

1. Dr Justin Daniels Present for all items
2. Ana Duarte Present for all items
3. Dr Steve Edwards Present for all items
4. Mohamad Farhat Present for all items
5. Professor G.J. Melendez-Torres Present for all items
6. Hugo Pedder Present for all items
7. Becky Pennington Present for all items
8. Dominic Pivonka Items 1.1 to 4.2.2

and 6.1 to 6.3.2

1. Dr Ravi Ramessur Present for all items
2. Dr Mohit Sharma Present for all items
3. Alan Thomas Present for all items
4. Jaqueline Tomlinson Present for all items
5. Min Ven Teo Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Sally Doss, Technical Adviser Items 1.1 to 4.2.2

Raphael Egbu, Technical Analyst Items 1.1 to 4.2.2

Joanna Richardson, Technical Adviser Items 5.1 to 5.2.2

Yelan Guo, Technical Adviser Items Items 6.1 to 6.2.2

Albany Chandler, Technical Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Angela Stainthorpe, Liverpool Reviews and Implementation Group (LRIG) Items 1.1 to 4.1.4

Janette Greenhalgh, Liverpool Reviews and Implementation Group (LRIG) Items 1.1 to 4.1.4

Sarah Davis, School of Health and Related Research (ScHARR) Item 5.1

Tessa Peasgood, School of Health and Related Research (ScHARR) Item 5.1

Ewen Cummins, Warwick Evidence Item 6.1

Lena Alkhudairy, Warwick Evidence Item 6.1

Mubarak Patel, Warwick Evidence Item 6.1

Clinical, Patient & NHS England experts present

Peter Clark, NHSE CDF clinical lead Items 1.1 to 4.2.2

Iain McNeish, clinical expert nominated by AstraZeneca Items 1.1 to 4.1.3

Rachel Downing, patient expert nominated by Target Ovarian Cancer Items 1.1 to 4.1.3

Nekma Meah, clinical expert nominated by the British Association of Dermatologists Items 5.1 to 5.1.4

Lynn Wilks, patient expert nominated by Alopecia UK Items 5.1 to 5.1.4

Dimitris Papamargaritis, clinical expert nominated by the Association for the Study of Obesity Items 6.1 to 6.1.

Jonathan Pinkney, clinical expert nominated by Eli Lilly & Company Items 6.1 to 6.1.

Sarah Le Brocq, patient expert nominated by All About Obesity Items 6.1 to 6.1.

Sanjeev Patel, NHSE clinical adviser (non-oncology) Items 6.1 to 6.3.2

Anurita Rohilla, Chief Pharmacist, Herts and West Essex ICB

Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Fiona MacPherson, Peter Baker, Pratheeban Nambyiah and Richard Ballerand.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 5 December 2024.

### Appraisal of [olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [ID6191]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11315)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11315).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Jaqueline Tomlinson (Lay), Dominic Pivonka (Cost).
  2. Part 2 –Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Draft Guidance (FDG). The committee decision was reached by consensus.

4.2.3. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11315>.

### Appraisal of [ritlecitinib for treating severe alopecia areata in people 12 years and over [ID4007]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11037)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://niceuk-my.sharepoint.com/personal/portia_dodds_nice_org_uk/Documents/ritlecitinib%20for%20treating%20severe%20alopecia%20areata%20in%20people%2012%20years%20and%20over%20%5bID4007%5d).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fotheringham.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11315>.

### Appraisal of Tirzepatidetirzepatide for managing overweight and obesity [ID6179]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly and Company.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/ta1026)
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Alan Thomas (Lay), Becky Pennington (Cost), Ian Bernstein (Clinical).
  2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee discussed confidential information submitted for this item.
     2. The committee requires further information before it can make a recommendation. The committee asked the NICE technical team to request this information from stakeholders.
     3. Further updates will be available on the topic webpage in due course: https://www.nice.org.uk/guidance/ta1026.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 13 February 2024 and will start promptly at 9:00.